Plain-English translation of NCT06269978 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new way to treat colorectal cancer that has spread to the lining of the abdomen (peritoneum). Instead of receiving chemotherapy through an IV in the arm, researchers are giving and (5FU) — two chemotherapy drugs — directly into the abdomen through a small permanent port. The goal is to find the safest dose and to see if this approach can help shrink tumors enough to make them treatable with surgery.
When colorectal cancer spreads to the lining of the abdomen, it can be very difficult to treat with standard chemotherapy alone. By delivering the medication directly to where the cancer is, doctors hope to get stronger effects on the cancer while potentially reducing side effects on the rest of the body.
You likely qualify if…
You likely don't qualify if…
You will have a small permanent port placed in your abdomen so the chemotherapy can be delivered directly. Then you will receive the medication through this port on days 1 and 15 of each 4-week cycle, with up to four cycles total (about 4 months of treatment). You will have several office visits for blood tests, imaging scans, and small biopsies to check how the treatment is working. The study includes follow-up visits for 30 days after treatment ends, and then longer-term monitoring if your cancer progresses or you start a new treatment.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States